ADH1 and ADH2 Disease Monitoring Study (DMS)

Running, not enrolling

Conditions studied: Autosomal Dominant Hypocalcemia

In brief

A global, multi-center, Disease Monitoring Study (DMS) in participants with Autosomal Dominant Hypocalcemia Type 1 (ADH1) or Autosomal Dominant Hypocalcemia Type 2 (ADH2) designed to characterize ADH1 and ADH2 disease presentation and progression through retrospective (past) and longitudinal prospective (over time into the future) data collection.

Key facts

Study ID
NCT05227287
Run by
Calcilytix Therapeutics, Inc., a BridgeBio company
People needed
95
Starts
2022-01-20
Expected to finish
2028-12-01
Last updated by the study team
2026-04-30

Who can join

Age: any, up to 90. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.